To keep her rheumatoid arthritis symptoms under control, to be able to function every day, once a month she gets an infusion of a biologic called Actemra, also known as tocilizumab. But now ...

Actemra (tocilizumab) is a prescription drug that’s used to treat certain conditions that affect your immune system. Actemra can cause side effects that range from mild to serious. Examples ...

Treatments for the disabling disease afflicting about 1.5 million Americans can have terrifying side effects, so doctors and patients were excited when Actemra reached the U.S. market in 2010.

Jan. 12 -- MONDAY, Jan. 11 (HealthDay News) -- Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat rheumatoid arthritis among people who haven't responded to ...

Actemra (tocilizumab) is a prescription drug that’s used for arthritis and other conditions. The drug is given as an injection under the skin or an intravenous (IV) infusion. Actemra’s dosage ...

ACTEMRA (tocilizumab) Injection by Genentech Genentech announced that the FDA has expanded the approved indication for Actemra (tocilizumab injection) for the treatment of adults with moderately ...

Roche's Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to shortages. Now, Sanofi's rival therapy Kevzara has also been hit by supply constraints.

Fifth phase III study for Actemra adds to body of evidence that Actemra is an important breakthrough in the treatment of rheumatoid arthritis Roche announced today that Actemra (tocilizumab ...

ZURICH, March 11 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab said on Thursday adding its drug Actemra to Gilead Sciences' (GILD.O), opens new tab Veklury medication, also called ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ...

The authorisation enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalised adult and paediatric patients Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX ...